Organogenesis Holdings Overview

  • Year Founded
  • 1985

Year Founded

  • Status
  • Public

  • Employees
  • 862

Employees

  • Stock Symbol
  • ORGO

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $2.47
  • (As of Tuesday Closing)

Organogenesis Holdings General Information

Description

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 85 Dan Road
  • Canton, MA 02021
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Organogenesis Holdings Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.47 $2.57 $1.96 - $4.71 $327M 133M 1.19M $0.04

Organogenesis Holdings Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 390,286 563,861 375,625 1,198,520
Revenue 435,474 433,140 450,893 467,359
EBITDA 36,229 36,031 40,322 86,998
Net Income 5,815 4,945 15,532 94,202
Total Assets 458,481 460,025 449,359 443,259
Total Debt 118,668 119,351 123,791 132,303
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Organogenesis Holdings Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Organogenesis Holdings‘s full profile, request access.

Request a free trial

Organogenesis Holdings Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercializa
Biotechnology
Canton, MA
862 As of 2023
00000
000000000 00 00000

000000

llum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000000000000
Marietta, GA
000 As of 0000
00000
000000000 00 00000

0000 0

smod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
0000000000000
Shanghai, China
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Organogenesis Holdings Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mimedx Corporation Marietta, GA 000 00000 000000000 00 00000
WuXi AppTec Formerly PE-Backed Shanghai, China 00000 00.000 000000000 00.000
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
Charles River Laboratories International Formerly PE-Backed Wilmington, MA 00000 00.000 000000000 00.000
Cipla Corporation Mumbai, India 00000 000000&0
You’re viewing 5 of 28 competitors. Get the full list »

Organogenesis Holdings Patents

Organogenesis Holdings Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022316212-A1 Porcine collagen compositions and methods of use thereof Pending 21-Jul-2021 00000000000
US-20240024429-A1 Porcine collagen compositions and methods of use thereof Pending 21-Jul-2021 000000000 0
CA-3227151-A1 Porcine collagen compositions and methods of use thereof Pending 21-Jul-2021 00000000000
EP-4373535-A2 Porcine collagen compositions and methods of use thereof Pending 21-Jul-2021 00000000000
AU-2022242840-A1 Methods kits and compositions for characterizing an anti-inflammatory response of a product Pending 23-Mar-2021 G01N33/5073
To view Organogenesis Holdings’s complete patent history, request access »

Organogenesis Holdings Executive Team (12)

Name Title Board Seat Contact Info
Gary Gillheeney Sr. Director, President, Chief Executive Officer & Chairman
David Francisco Chief Financial Officer
Patrick Bilbo Chief Operating Officer, Operations
Lori Freedman JD Chief Administrative Officer, Administration & Chief Legal Officer, Legal
Brian Grow Executive
You’re viewing 5 of 12 executive team members. Get the full list »

Organogenesis Holdings Board Members (12)

Name Representing Role Since
0000 0000 Organogenesis Holdings Board Member 000 0000
000000 000000000 Organogenesis Holdings Board Member 000 0000
00000 00000 Organogenesis Holdings Board Member 000 0000
0000 0000000000 00 Organogenesis Holdings Director, President, Chief Executive Officer & Chairman 000 0000
00000 00000000 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Organogenesis Holdings Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Organogenesis Holdings Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CPN Biosciences 17-Sep-2020 0000000000 0000 Medical Supplies 0000 0000
Avista Healthcare Public Acquisition 10-Dec-2018 0000000000 Special Purpose Acquisition Company (SPAC) 0000 0000
NuTech Medical 24-Mar-2017 0000000000 000.00 Surgical Devices 0000 0000
Shire (Dermagraft business) 17-Jan-2014 0000000000 00000 Pharmaceuticals
NanoMatrix 25-Feb-2008 Merger/Acquisition Biotechnology 00000 000
To view Organogenesis Holdings’s complete acquisitions history, request access »

Organogenesis Holdings Subsidiaries (1)

Company Name Industry Location Founded
CPN Biosciences Medical Supplies Largo, FL
To view Organogenesis Holdings’s complete subsidiaries history, request access »

Organogenesis Holdings ESG

Risk Overview

Risk Rating

Updated September, 16, 2023

27.58 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Organogenesis Holdings’s complete esg history, request access »

Organogenesis Holdings FAQs

  • When was Organogenesis Holdings founded?

    Organogenesis Holdings was founded in 1985.

  • Who is the CEO of Organogenesis Holdings?

    Gary Gillheeney Sr. is the CEO of Organogenesis Holdings.

  • Where is Organogenesis Holdings headquartered?

    Organogenesis Holdings is headquartered in Canton, MA.

  • What is the size of Organogenesis Holdings?

    Organogenesis Holdings has 862 total employees.

  • What industry is Organogenesis Holdings in?

    Organogenesis Holdings’s primary industry is Biotechnology.

  • Is Organogenesis Holdings a private or public company?

    Organogenesis Holdings is a Public company.

  • What is Organogenesis Holdings’s stock symbol?

    The ticker symbol for Organogenesis Holdings is ORGO.

  • What is the current stock price of Organogenesis Holdings?

    As of 18-Jun-2024 the stock price of Organogenesis Holdings is $2.47.

  • What is the current market cap of Organogenesis Holdings?

    The current market capitalization of Organogenesis Holdings is $327M.

  • What is Organogenesis Holdings’s current revenue?

    The trailing twelve month revenue for Organogenesis Holdings is $435M.

  • Who are Organogenesis Holdings’s competitors?

    Mimedx, WuXi AppTec, AbbVie, Charles River Laboratories International, and Cipla are some of the 28 competitors of Organogenesis Holdings.

  • What is Organogenesis Holdings’s annual earnings per share (EPS)?

    Organogenesis Holdings’s EPS for 12 months was $0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »